REFERENCES
1. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635-48.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
3. Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric cancer: where are we heading? Dig Dis. 2020;38:280-5.
4. Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286-287:18-24.
5. Zhang Z, Liu N, Sun M. Research progress of immunotherapy for gastric cancer. Technol Cancer Res Treat. 2023;22:15330338221150555.
6. Gullo I, Carneiro F, Oliveira C, Almeida GM. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology. 2018;85:50-63.
7. Malfait F, Syx D, Vlummens P, et al. Musculocontractural ehlers-danlos syndrome (former EDS type VIB) and adducted thumb clubfoot syndrome (ATCS) represent a single clinical entity caused by mutations in the dermatan-4-sulfotransferase 1 encoding CHST14 gene. Hum Mutat. 2010;31:1233-9.
8. Miyake N, Kosho T, Mizumoto S, et al. Loss-of-function mutations of CHST14 in a new type of Ehlers-Danlos syndrome. Hum Mutat. 2010;31:966-74.
9. Janecke AR, Baenziger JU, Müller T, Dündar M. Loss of dermatan-4-sulfotransferase 1 (D4ST1/CHST14) function represents the first dermatan sulfate biosynthesis defect, "dermatan sulfate-deficient adducted thumb-clubfoot syndrome". Hum Mutat. 2011;32:484-5.
10. Mendoza-Londono R, Chitayat D, Kahr WH, et al. Extracellular matrix and platelet function in patients with musculocontractural Ehlers-Danlos syndrome caused by mutations in the CHST14 gene. Am J Med Genet A. 2012;158A:1344-54.
11. Kosho T. CHST14/D4ST1 deficiency: New form of Ehlers-Danlos syndrome. Pediatr Int. 2016;58:88-99.
12. Mizumoto S, Kosho T, Hatamochi A, et al. Defect in dermatan sulfate in urine of patients with Ehlers-Danlos syndrome caused by a CHST14/D4ST1 deficiency. Clin Biochem. 2017;50:670-7.
13. Sandal S, Kaur A, Panigrahi I. Novel mutation in the CHST14 gene causing musculocontractural type of Ehlers-Danlos syndrome. BMJ Case Rep. 2018;2018:bcr-2018.
14. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175:8-26.
15. Kosho T, Mizumoto S, Watanabe T, Yoshizawa T, Miyake N, Yamada S. Recent advances in the pathophysiology of musculocontractural Ehlers-Danlos syndrome. Genes. 2019;11:43.
16. Bian S, Akyüz N, Bernreuther C, et al. Dermatan sulfotransferase Chst14/D4st1, but not chondroitin sulfotransferase Chst11/C4st1, regulates proliferation and neurogenesis of neural progenitor cells. J Cell Sci. 2011;124:4051-63.
17. Zavros Y, Merchant JL. The immune microenvironment in gastric adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2022;19:451-67.
18. Uppal A, Dehal A, Chang SC, et al. The immune microenvironment impacts survival in western patients with gastric adenocarcinoma. J Gastrointest Surg. 2020;24:28-38.
19. Wang B, Zhang Z, Liu W, Tan B. Targeting regulatory T cells in gastric cancer: pathogenesis, immunotherapy, and prognosis. Biomed Pharmacother. 2023;158:114180.
20. Jia L, Wang T, Zhao Y, et al. Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas. Oncoimmunology. 2021;10:1969767.
21. Sathe A, Grimes SM, Lau BT, et al. Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment. Clin Cancer Res. 2020;26:2640-53.
22. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-96.
23. Zhou J, Zhang S, Guo C. Crosstalk between macrophages and natural killer cells in the tumor microenvironment. Int Immunopharmacol. 2021;101:108374.
24. Zhang X, Xu W. Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway. Gut. 2017;66:1878-80.
25. Iversen DB, Andersen NE, Dalgård Dunvald AC, Pottegård A, Stage TB. Drug metabolism and drug transport of the 100 most prescribed oral drugs. Basic Clin Pharmacol Toxicol. 2022;131:311-24.
26. Liu YN, Chen J, Wang J, et al. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism. Arch Toxicol. 2023;97:2133-42.
27. Hulshof EC, Deenen MJ, Nijenhuis M, et al. Correction: dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. Eur J Hum Genet. 2023;31:1088-9.
28. Haerian BS, Roslan H, Raymond AA, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure. Seizure;19:339-46.
29. Liu H, Li Y, Karsidag M, Tu T, Wang P. Technical and biological biases in bulk transcriptomic data mining for cancer research. J Cancer. 2025;16:34-43.
30. Liu H, Guo Z, Wang P. Genetic expression in cancer research: challenges and complexity. Gene Rep. 24;37:102042.
31. Wang TT, Zhao YL, Peng LS, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66:1900-11.
